We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




MicroRNA Mimic Shown to Reverse Effects of Pulmonary Fibrosis

By LabMedica International staff writers
Posted on 29 Sep 2014
Print article
A potential new treatment that reverses the effects of pulmonary fibrosis, a respiratory disease in which scars develop in the lungs and greatly suppress breathing, is being assessed by scientists. The therapy uses a microRNA mimic, miR-29, which is delivered to lung tissue intravenously. In lab mice, miR-29 not only blocked pulmonary fibrosis, it reversed fibrosis after several days.

The findings were published September 19, 2014, in the journal EMBO Molecular Medicine. “The mimic, when injected into the blood, goes to the lung and it has a sustained effect. We are very impressed that it can reverse fibrosis, not only prevent it,” said Naftali Kaminski, MD, a professor at the Yale School of Medicine (New Haven, CT, USA), and section chief of pulmonary, critical care, and sleep medicine, and corresponding author of the study.

The research is a collaboration between Yale and miRagen Therapeutics Boulder, CO, USA), a pharmaceutical company. The company had developed miR-29 earlier as a possible therapy for cardiac disease. Dr. Kaminski, whose group innovated research in microRNA in lung fibrosis, visualized the potential for use of miR-29 in pulmonary fibrosis, as did Dr. Eva van Rooij, the scientist who discovered the role for miR-29 in cardiac fibrosis, and is a senior coauthor on the study. “I’m particularly excited about working with this microRNA,” said Dr. van Rooij. “All evidence points to it being a master regulator of fibrosis.”

The next phase of the study, according to Dr. Kaminski, will be to begin evaluating miR-29 as a therapeutic for human idiopathic pulmonary fibrosis (IPF). Once considered a rare disease, IPF now affects more than 200,000 people in the United States, where approximately 30,000 people die from IPF every year. The median survival from diagnosis is three to five years, and in spite of recent potential developments, there is no intervention that reverses the disease.

Related Links:
Yale School of Medicine
miRagen Therapeutics


Gold Member
Turnkey Packaging Solution
HLX
Unit-Dose Packaging solution
HLX
New
Automated Cell Counter
QuadCount
New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: Schematic overview of maternal biomarker discovery using cell-free RNA during pregnancy (Photo courtesy of Circulation Research (2024). DOI: 10.1161/CIRCRESAHA.124.325024)

Maternal Blood Test Identifies Congenital Heart Diseases in Fetus

Each year, around 1,000 children are born with a single ventricle heart defect (SVHD), a condition where one of the heart's lower chambers is underdeveloped, too small, or missing a valve.... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.